PHARMACOKINETICS, EFFICACY AND SAFETY OF SUBCUTANEOUS VERSUS INTRAVENOUS RITUXIMAB IN CHINESE PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA: A RANDOMIZED TRIAL

Yan Gao,L. Zhang,Sujun Gao,Yang Yu,Q. Zhang,Haiyang Zhang,Ping He,Fēi Li,Hongmei Jing,Susan Grange,Lilian Bu,Qun Wang,Yan Wang,Hui Huang

DOI: https://doi.org/10.1002/hon.3165_567

IF: 4.85

2023-01-01

Hematological Oncology

Abstract:Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin’s lymphoma (NHL) in China. The standard of care for DLBCL is intravenous (IV) rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Compared with IV administration, subcutaneous (SC) administration of rituximab is faster, less invasive, and reduces patients’ treatment burden. Global trials have shown that SC rituximab, dosed at 1400 mg, had non-inferior rituximab serum levels and comparable efficacy and safety to IV rituximab at 375 mg/m2 in patients with NHL; however, data in Chinese patients are lacking. Methods: This was a Phase II, randomized, controlled, open-label study conducted in nine centers in China from February 2021 to May 2022 (NCT04660799). Patients aged 18–80 years with untreated CD20-positive (CD20+) DLBCL were randomized 1:1 to receive either one cycle of IV rituximab plus seven cycles of SC rituximab (RSC-CHOP), or eight cycles of IV rituximab (RIV-CHOP); both combined with six or eight cycles of CHOP every 3 weeks. IV and SC rituximab were dosed at 375 mg/m2 and 1400 mg, respectively. Patients were stratified during randomization based on International Prognostic Index (IPI) scores (IPI 0–2 versus 3–5). The primary endpoint was the ratio of trough rituximab serum concentration of SC to IV rituximab (Ctrough,SC/Ctrough,IV) at Cycle 7. Non-inferiority of Ctrough,SC versus Ctrough,IV will be shown if the lower limit of the two-sided 90% confidence interval (CI) exceeded 0.80. Complete response rate (CRR) was assessed by an Independent Review Committee (IRC) using Lugano Response Criteria for Malignant Lymphoma. Safety, tolerability and immunogenicity were also evaluated. Results: Fifty patients were enrolled: 26 received RSC-CHOP and 24 received RIV-CHOP. Median age was 61.5 (range 19–79) years. The baseline stratification characteristics of IPI scores were well-balanced between both arms; 21 (42.0%) patients had an IPI score of 3–5. Most patients in both SC (24/26, 92.3%) and IV (19/24, 79.2%) rituximab arms completed all eight cycles of rituximab. Geometric mean ratio of Ctrough,SC/Ctrough,IV at Cycle 7 was 1.52 (90% CI 1.28–1.79), demonstrating non-inferiority for SC rituximab versus IV rituximab (Table 1). The IRC-assessed CRR in the SC rituximab arm (80.8%; 95% CI 60.7–93.5) was similar to that in the IV rituximab arm (62.5%; 95% CI 40.6–81.2). There were no new clinically relevant safety findings, and the incidence of adverse events was comparable between both arms, in line with previous global studies on SC rituximab. Conclusion: SC rituximab demonstrated non-inferior rituximab serum trough levels and comparable efficacy and tolerability to IV rituximab in Chinese patients with previously untreated CD20+ DLBCL. SC rituximab is a viable route of administration, with potential to reduce burden of administration. Encore Abstract—previously submitted to EHA 2023 The research was funded by: This study was sponsored by F. Hoffmann-La Roche Ltd. Keywords: aggressive B-cell non-Hodgkin lymphoma, chemotherapy, combination therapies Conflicts of interests pertinent to the abstract S. Grange Employment or leadership position: Susan Grange is an employee of F. Hoffmann-La Roche Ltd. L. Bu Employment or leadership position: Lilian Bu is an employee of F. Hoffmann-La Roche Ltd. Q. Wang Employment or leadership position: Qianming Wang is an employee of F. Hoffmann-La Roche Ltd. Y. Wang Employment or leadership position: Yanjie Wang was an employee of F. Hoffmann-La Roche Ltd, but is no longer with F. Hoffmann-La Roche Ltd as of 9 March 2023.